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Long noncoding RNAs (lncRNAs) impart significant regulatory
functions in a diverse array of biological pathways and manipu-
lation of these RNAs provides an important avenue to modu-
late such pathways, particularly in disease. Our knowledge about
lncRNAs’ role in determination of cellular fate during HIV-1 infection
remains sparse. Here, we have identified the impact of the lncRNA
SAF in regulating apoptotic effector caspases in macrophages, a long-
lived cellular reservoir of HIV-1, that are largely immune to virus-
induced cell death. Expression of SAF is significantly up-regulated in
HIV-1–infected human monocyte-derived macrophages (MDM) com-
pared with bystander and virus-nonexposed cells. A similar enhance-
ment in SAF RNA expression is also detected in the HIV-1–infected
airway macrophages obtained by bronchoalveolar lavage of HIV-1–
infected individuals. Down-regulation of SAF with siRNA treatment
increases caspase-3/7 activity levels in virus-infected MDMs. This in-
duction of apoptotic caspases occurs exclusively in HIV-1–infectedmac-
rophages and not in bystander cells, leading to a significant reduction
in HIV-1 replication and overall viral burden in the macrophage cul-
ture. This study identifies targeting of the lncRNA SAF as a potential
means to specifically induce cell death in HIV-1–infected macrophages.
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Cell death is a prominent feature of HIV-1 pathogenesis thatis characterized by severe loss of T lymphocytes and other
immune cells during the disease progression (1–6). Infection of
activated CD4+ T cells, the primary target of HIV-1, results in
efficient and productive virus replication but rapidly leads to a
virus-induced cytopathic death of the infected cells (7). Another
cellular target of HIV-1 infection are the different macrophage
lineages (8). Tissue macrophages are long-lived cells that are
maintained in their local tissue environment through self-renewal
(9–12). These myeloid cells reside in various tissues and vary in
their phenotype and function depending upon their location (13).
Several tissue macrophages such as brain microglia, liver Kupffer
cells, and alveolar macrophages have long been recognized to
harbor and support HIV-1/Simian immunodeficiency virus (SIV)
infection at different stages of the disease (14–21). In fact, in recent
studies, using humanized myeloid-only mice and CD4+ T cell-
depleted rhesus macaques, it has been shown that tissue macro-
phages can support HIV-1/SIV replication and maintain prolonged
plasma viremia even in the absence of T cells (22–24). Although the
half-life of infected macrophages estimated on the basis of the viral
decay kinetics in these macaques was determined to be relatively
short, the high viral burden, rapid rate of disease progression, and
aberrant immune activation in the CD4+ T cell-depleted milieu
may all impact the macrophage half-life. Nonetheless, these studies
emphasize the contribution of tissue macrophages to HIV-1/SIV
viral persistence. Moreover, several other in vivo and in vitro
studies indicate that in comparison with CD4+ T cells, macro-
phages support relatively lower levels of HIV-1 replication and are
relatively resistant to virus-induced cell death (25–28). This unique
ability of macrophages to sustain viral replication while retaining
extended cell survival makes them an ideal candidate for viral
persistence even during long-term antiretroviral therapy, which
poses a major hurdle in the HIV-1 cure efforts. A complex host-
pathogen interaction must be in play to maintain such a delicate
balance between productive HIV-1 infection and macrophage
survival. A comprehensive understanding of how HIV-1 modulates
cell death and/or survival pathways in infected macrophages is likely
to be a requirement for the effective elimination of the infection.
Apoptosis is the most commonly reported form of virus-induced
programmed cell death, and several studies have examined the
mechanisms involved in induction or evasion of apoptosis by HIV-1
(29–31). These studies are mainly focused on the role of various
protein modulators, either viral (HIV-1 Nef, Vpr, Tat, and Env)
or cellular (Fas, TNF-α, Bcl-2, Bax, FLICE, p53) factors (32–34).
However, there is only limited information available on how HIV-1
infection affects nonprotein-coding regulatory elements such as
the long noncoding RNAs (lncRNA). lncRNAs are RNA tran-
scripts that are larger than 200 nucleotides in length yet lack a
protein-coding ORF. They are now known to play a significant
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role in regulating diverse cellular pathways both in health and
disease, including viral infections such as HIV-1 (35, 36). The
lncRNAs NEAT1 and NRON have been shown to inhibit HIV
replication by regulating nuclear localization of viral transcripts
(37, 38). Several lncRNAs modulate cell apoptotic pathways at
both extrinsic and intrinsic levels. For instance, SAF (FAS-AS1)
and HOXA-AS2 are antiapoptotic lncRNAs that regulate death
receptor functions in the extrinsic pathway, while the lncRNAs
Malat1, GAS5, and MEG3 act on the intracellular regulator
p53 to induce apoptosis (39–43). The possible roles of such
lncRNAs during HIV-1 infection have yet to be explored.
In the current study, we determined that the lncRNA ex-
pression profile in HIV-1–infected human macrophages was
distinct from that of their noninfected counterparts. We utilized
an in vitro HIV-1 infection model of human primary monocyte-
derived-macrophage (MDM) culture to quantify and compare
expression of 90 well-characterized lncRNAs in three MDM cell
populations: HIV-1–infected, HIV-1–exposed but uninfected
bystander, and virus-nonexposed control MDMs. Across the
panel of 90 lncRNAs, we observed significant up-regulation in
expression of the lncRNA SAF (FAS-AS1) in HIV-1–infected
MDMs in comparison with both bystander and nonexposed cells.
Moreover, we also found that SAF expression was up-regulated
in HIV-1–infected airway macrophages recovered by bron-
choalveolar lavage (BAL) from HIV-1-positive donors from
Malawi. SAF is an antiapoptotic lncRNA that protects against
Fas-mediated programmed cell death (43–45). We further
demonstrated that siRNA-mediated down-regulation of the
lncRNA SAF in MDMs led to activation of apoptotic effector
caspase-3/7 specifically in HIV-1–infected cells but not in by-
stander cells. The increase in cell death lead to a reduction in
viral burden in the MDM culture, indicating a potential oppor-
tunity to reduce or eliminate HIV-1–infected macrophage res-
ervoirs by modulation of lncRNA-mediated cell survival.
Results
HIV-1 Infection of Human MDMs Does Not Activate Apoptotic Effector
Caspases or Lead to Cell Death. To understand the dynamics of
viral replication and activation of apoptosis in HIV-1–infected
primary macrophages, humanMDMs were infected with a replication-
competent vesicular stomatitus virus-G (VSV-G) pseudotyped
glycoprotein pseudotyped HIV-1 (isolate HXB3) virus (HXB3) virus
expressing a R5-tropic BaL envelope (HXB3/BaL) and monitored
up to 11 d postinfection (dpi) for viral infection and induction of
apoptosis. As illustrated in Fig. 1A, HIV-1–infected macrophages
were distinguished from uninfected bystanders by flow cytometric
detection of intracellular expression of the viral capsid (p24)
protein. The proportion of p24-positive HIV-1–infected cells
within the virus-infected culture increased progressively from
9.2% on 1 dpi to 36.5% on 11 dpi when the experiment was ter-
minated (Fig. 1B). This demonstrates that HIV-1 establishes a
productive and spreading viral infection in the primary macro-
phage culture. However, this productive infection did not increase
cell death in the infected culture. Throughout the 11 d of in-
fection, cell viability remained high in infected (mean, 97 ± 1.7%),
and in bystander (95 ± 1.4%) or nonexposed (96 ± 0.8%) cells
(Fig. 1C). Level of active caspase-3/7, which are effector proteases
of apoptosis, remained low in infected cells (2.5–11.4%), at levels
of expression comparable to those of bystander (4.4–7.3%) and
nonexposed cells (3.5–8.5%) throughout the infection (Fig. 1D).
Together, these data indicate that primary human macrophages
support productive HIV-1 infection but resist the activation of
apoptotic effector caspases and cell death that is usually asso-
ciated with HIV-1 infection of lymphocytes.
Expression of lncRNA SAF Is Up-Regulated in HIV-1–Infected MDMs.
There is increasing evidence that lncRNAs play important roles
in HIV-1 infection. However, most reports have focused on
identifying those lncRNAs that impact viral replication (37, 38).
The differential expression of lncRNAs in HIV-1–infected and
exposed but uninfected macrophages has not been explored. To
Fig. 1. HIV-1 infection and apoptosis in MDMs. (A) Representative flow
cytometry plots showing HIV-1 p24 staining of MDMs and demarcation of
virus-nonexposed (Green), virus-exposed but uninfected bystander (Blue),
and virus-infected (Red) cells. Cells were gated for singlets (FSC-H vs. FSC-A)
and MDM (SSC-A vs. FSC-A) before analysis of HIV-1 p24 expression. (B) The
percentage (mean ± SEM) of HIV-1–infected MDMs was determined by flow
cytometry staining with PE-conjugated anti-p24 antibody on days 1, 4, 8, and
11 postinfection (n = 4). (C and D) The percentage (mean ± SEM) of viable (C)
and active caspase 3-positive (D) MDMs was determined by flow cytometry
staining with fixable viability dye eFluor506 and CellEvent caspase-3/7 green
detection reagent, respectively, within virus-nonexposed (green), bystander
(blue), and infected (red) cells at indicated days postinfection (n = 4).
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identify the lncRNAs that are differentially expressed in HIV-1–
infected versus bystander cells, we infectedMDMs with a replication-
competent mCherry-reporter HIV-1 virus for 7 d and sorted HIV-1–
infected (mCherry-positive) and bystander (mCherry-negative)
MDMs. Uninfected, nonexposed MDMs were also processed
through the cell sorter as control cells. The expression levels of
90 well-characterized lncRNAs, including a number of lncRNAs
implicated in apoptosis, were determined using a quantitative
real-time PCR (qRT-PCR) based array. Out of the 90, expression
of 71 lncRNAs was detected in all three groups and therefore was
used for further analysis (SI Appendix, Fig. S1). Comparison of the
lncRNA expression profile among nonexposed, bystander, and
virus-infected MDMs revealed that 18 lncRNAs were up-regulated
(≥twofold) and 17 were down-regulated (≤twofold) in HIV-1–
infected MDMs, whereas in bystander cells only six were up-
regulated. A considerable number of lncRNAs (36 out of 71)
were down-regulated in the bystander MDMs (Fig. 2A). Changes
in 19 lncRNAs followed a similar pattern in both virus-infected
and bystander cells. A further examination of the 16 lncRNAs
that were differentially expressed in HIV-1–infected MDMs (Fig.
2B) revealed that the change was most pronounced in the lncRNA
SAF. This antiapoptotic lncRNA had the highest increase in
expression in HIV-1–infected cells but exhibited minimal up-
regulation in the bystander MDMs, indicating that this varia-
tion was likely to be HIV-1 infection-specific. To further validate
this lncRNA profiler array data, we measured SAF expres-
sion in HIV-1–infected, bystander, and nonexposed cells using
a different set of published qRT-PCR primers (43) in four
independent MDM cultures. Consistent with the lncRNA pro-
filer data, the independent qRT-PCR results (Fig. 2C) con-
firmed that SAF expression is significantly elevated in HIV-1–
infected cells compared with bystander or virus-nonexposed
control MDMs.
Expression of lncRNA SAF Is Enhanced in HIV-1–Infected Human BAL-
Derived Airway Macrophages. To determine if the increase in SAF
expression observed in MDMs in vitro also occurs in vivo during
HIV-1 infection, we measured SAF expression in bronchoalveolar
lavage (BAL)-derived airway macrophages from HIV-1–infected
individuals. Airway macrophages in HIV-1–infected individuals
have previously been shown to harbor the virus, and viral RNA
has been detected by fluorescent in situ hybridization (FISH) and
PCR-based assays (14, 46). We obtained airway macrophages
from three HIV-1–infected, antiretroviral therapy naïve individuals
by BAL. Following a previously published gating strategy for human
BAL cells (14, 47), the two major targets of HIV-1, macrophages
and lymphocytes, can be differentiated on the basis of their
relative size and granularity. Surface marker analysis of the cells
gated as macrophages demonstrates that they uniformly express
the macrophage surface markers CD206 and CD169 (47), while
the smaller cells gated as lymphocytes do not (Fig. 3A). HIV-1–
infected cells within this airway macrophage population were
detected and flow sorted on the basis of FISH staining with
fluorescent (Quasar 670)-labeled HIV-1 Nef probes (Fig. 3B).
Analysis of the Nef-positive cell population by qRT-PCR dem-
onstrated a two to threefold higher level of Nef RNA transcripts
in those cells (Fig. 3C), indicating an enrichment of infected cells
through flow cytometry sorting. When we compared the levels of
expression of the lncRNA SAF, we found that SAF RNA tran-
scripts were approximately sixfold more abundant in Nef-positive
cells in comparison with the Nef-negative cells in two of the three
individuals (Fig. 3D). Expression of SAF could not be compared
in the third individual as it was undetectable by PCR amplifi-
cation in the Nef-positive cells. These data indicate that during
natural HIV-1 infection, the virus induces enhancement of SAF
expression levels in human airway macrophages comparable to
those observed in MDMs in vitro.
Fig. 2. lncRNA SAF expression in HIV-1–infected MDMs. (A) Venn diagram
summarizing changes in lncRNA expression profile in HIV-1–infected and
bystander cells compared with virus-nonexposed MDMs. At least twofold up-
or down-regulation compared with nonexposed MDMs was considered as a
change in expression. (B) A summary of the relative expressions of the
16 lncRNAs that were differentially expressed in HIV-1–infected (red dot)
MDMs compared with bystander (blue box) cells. The lncRNA SAF is identi-
fied with a box. (C) Fold changes (mean ± SEM) in expression of the lncRNA
SAF were determined by qRT-PCR in nonexposed, bystander, and virus-
infected MDMs (n = 4). Significance of difference among groups de-
termined by one-way ANOVA is indicated above the groups, *P < 0.05.





















Inhibition of lncRNA SAF Activates Apoptotic Effector Caspase-3/7 in
HIV-1–Infected MDMs. The lncRNA SAF has been shown to pro-
tect cells from induction of apoptosis (44, 45). Since expression
of SAF was up-regulated in HIV-1–infected macrophages both
in vivo and in vitro, we tested if the lncRNA SAF is directly
involved in the protection of HIV-1–infected MDMs against
virus-induced cell death. We used siRNA to reduce SAF expres-
sion levels in MDMs. Using Viromer Blue transfection reagent
and a Cy3-labeled siRNA, we achieved an average transfection
efficiency of about 70% in MDMs (SI Appendix, Fig. S2 A and
B). Transfection of MDMs with siSAF resulted in a threefold
reduction in SAF lncRNA level in comparison with cells treated
with negative-control siRNA (NC1), demonstrating that the SAF
lncRNA level in MDM can be effectively manipulated with
siRNAs (SI Appendix, Fig. S2C). Next, to assess how down-
regulation of SAF expression in HIV-1–infected MDMs im-
pacts activation of caspase-3/7, we infected MDMs with VSV-G
pseudotyped HIV-1 (HXB3/BaL) virus, allowed the infection to
establish for 4 d, and then treated the MDMs with either siSAF
or control NC1 siRNA (Fig. 4A). As shown in Fig. 4 B and C,
control NC1 siRNA treatment of MDMs did not have a sub-
stantial effect on active caspase-3/7 levels, but siSAF treatment
led to a significant induction in active caspase-3/7 in HIV-1–
infected MDMs compared with untreated or NC1 control siRNA-
treated MDMs. After 1 d of transfection, there were approximately
threefold more cells expressing active caspase-3/7 within HIV-1–
infected MDMs in siSAF-treated culture than control NC1-treated
or untreated MDMs (Fig. 4C). On day 3 posttransfection, although
the number of active caspase-3/7–positive cells was still signifi-
cantly higher among HIV-1–infected MDMs in siSAF-treated
culture, the effect of siSAF appeared to wane (Fig. 4C). In
contrast to HIV-1–infected MDMs, active caspase-3/7 levels in
neither the nonexposed nor the bystander cells were significantly
affected by the siSAF treatment (Fig. 4 E and F). Although
siSAF treatment led to a rapid induction of active caspase-3/7 on
day 1, significant loss of cell viability in HIV-1–infected MDMs
was only observed on day 3 posttransfection, which is consistent
with the progressive nature of a programmed cell death pathway
(Fig. 4D). Virus-nonexposed and bystander cells again did not
show any increase in cell death due to siSAF treatment (Fig. 4F).
These data strongly indicate that siSAF treatment can induce
activation of apoptotic effector caspases and cell death specifically
in HIV-1–infected macrophages while the uninfected bystander
cells remain largely unaffected.
Inhibition of lncRNA SAF Reduces HIV-1 Infection Burden in MDMs.As
siSAF treatment rendered HIV-1–infected MDMs significantly
more prone to activation of apoptotic effector caspases, we ex-
amined how this affected total HIV-1 viral burden in the MDM
culture. We assessed this first by identification of HIV-1 p24-
positive cells within the culture and observed that the proportion
of virus-infected cells was reduced significantly on day 1 post
siSAF treatment (Fig. 5 A and B). The effect was even further
pronounced by day 3 posttransfection when the proportion of
HIV-1–infected cells in siSAF-treated culture was about 67–75%
lower than control NC1-treated or untreated cultures, respectively
(Fig. 5B). We then quantified HIV-1 viral RNA transcript levels in
the cells to compare ongoing viral replication in the MDM cul-
tures. As shown in Fig. 5 C and D, levels of both Gag and Nef viral
RNA were significantly reduced in siSAF-treated MDMs as early
as day 1 posttransfection and remained low for 3 d. We noted that
the control NC1 siRNA treatment caused a slight reduction in the
viral RNA levels on day 1, but the levels recovered to those of
untreated cells by day 3 posttransfection. Finally, we assessed the
effect of siSAF treatment on virus production and spreading by
measuring virion-associated p24 protein levels in the culture
supernatants. Consistent with a reduced viral RNA transcript level,
the amount of viral p24 protein was significantly decreased in the
culture supernatant by day 1 and remained so 3 d posttransfection
(Fig. 5E). These results determine that siSAF treatment leads to a
Fig. 3. Expression of lncRNA SAF in BAL-derived airway macrophages from HIV-1–infected individuals. (A) Representative flow cytometry plots showing the
gating strategy and surface expression of CD206 and CD169 in macrophages and lymphocytes, performed on study participant HITUB1096Z. (B) Represen-
tative flow cytometry plots showing gating strategy for sorting Nef-positive and Nef-negative BAL-derived airway macrophages. BAL cells were first gated for
singlets (FSC-H vs. FSC-A) and then macrophages (SSC-A vs. FSC-A) before analysis of HIV Nef-Quasar670 probe staining. (C) Fold changes (mean ± SEM) in
expression of the HIV-1 Nef RNA was determined by qRT-PCR in Nef-negative and Nef-positive airway macrophages (n = 3). (D) Fold changes (mean ± SEM) in
expression of the lncRNA SAF was determined by qRT-PCR in Nef-negative and Nef-positive airway macrophages (n = 2). This analysis was performed on study
participants AMAC282, AMAC283, and AMAC292.
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marked reduction in HIV-1 replication and total viral burden in the
MDM culture.
Discussion
It has become increasingly evident that lncRNAs play an im-
portant role in the virus–host interaction and pathogenesis. In
the context of HIV-1 infection, studies on lncRNA expression
and their role in viral pathogenesis have mostly been limited to
viral infection of lymphoid or monocytic cell lines (35–38). In
addition, most of these studies compared data from HIV-1–
infected cultures as a whole to that of uninfected cultures with-
out assessing potential changes to uninfected bystander cells that
were nonetheless exposed to virus. Since only a fraction of the
virus exposed cells become productively infected with HIV-1, a
scenario that is particularly true of macrophages, this approach
has a reduced capacity to discriminate between alterations in HIV-1–
infected versus bystander cells within the same culture. In the
current study, we describe the impact of HIV-1 infection on
lncRNA expression in a primary human cell of myeloid origin
specifically delineating the differences between virus-infected and
bystander cells. These two cell subsets showed dramatic differences
in lncRNA expression levels upon exposure to HIV-1 virus. Only
Fig. 4. Effect of siSAF treatment on apoptosis of HIV-1–infected MDMs. (A) Schematic presentation of the experiment timeline. MDMs were transfected with
negative-control siRNA (NC1) or siSAF 4 d after infection with HIV-1 virus and analyzed for induction of apoptosis and cell death on day 1 and day 3 post-
transfection. Each arrow indicates a day. (B and E) Representative flow cytometry plots showing active caspase 3 staining of HIV-1–infected (B) or nonexposed and
bystander (E) MDMs with or without siRNA treatment, as indicated above the panel. Infected and bystander cells were determined based on HIV-1 p24 staining of
cells with preceding gating for singlets (FSC-H vs. FSC-A) and MDM (SSC-A vs. FSC-A). (C and F) The percentage of active caspase three positive cells (mean ± SEM)
was determined by flow cytometry staining with CellEvent caspase-3/7 green detection reagent in virus-infected (C) or nonexposed and bystander (F) MDMs on day
1 (blue bar) and day 3 (red bar) post siRNA transfection (n = 4). (D andG) The percentage of dead cells (mean± SEM) was determined by flow cytometry with fixable
viability dye eFluor506 in virus-infected (D) or nonexposed and bystander (G) MDMs on day 1 (blue bar) and day 3 (red bar) post siRNA transfection (n = 4). HIV,
virus-infected and untreated; HIV-NC1, virus-infected and negative-control siRNA NC1-treated; HIV-siSAF, virus-infected and siSAF-treated. Significance of difference
among groups determined by one-way ANOVA is indicated above the groups, *P < 0.05, **P < 0.01, and ***P < 0.001.





















19 lncRNAs shared a similar pattern of expression in both infected
and bystander MDMs compared with control, nonexposed MDMs.
In contrast, most of the differentially expressed lncRNAs were
up-regulated in HIV-1–infected MDMs, while exposed but
uninfected bystander cells showed a pattern of down-regulation
in expression of those specific lncRNA species. Although we
focused our study on SAF, which was the most up-regulated
lncRNA, the second most up-regulated lncRNA on the list
was lincRNA-p21 that has recently been shown to play an im-
portant antiapoptotic role during HIV-1 infection in tissue culture
(48). These findings demonstrate how HIV-1 cellular infection
status differentially affects lncRNA expression levels and empha-
sizes the importance of distinguishing between the infected and
bystander cell subsets during studies of virus-induced alterations in
cellular pathways.
The lncRNA that was most markedly affected by HIV-1
infection in MDMs was SAF (FAS-AS1). It is a 1.5-kb antisense
lncRNA that is transcribed from the intron 1 region of the Fas
gene (43). Expression of this lncRNA has been shown to prevent
apoptosis by inducing alternative splicing of the Fas gene and
thereby increasing production of soluble FAS from the cells (45).
Our data revealed that expression of this antiapoptotic lncRNA
SAF was significantly up-regulated in HIV-1–infected MDMs in
comparison with bystander and nonexposed cells. Significantly, a
similar increase in SAF expression was also observed in HIV-1–
infected airway macrophages from HIV-1–infected human volun-
teers. Interestingly, in contrast to our findings in MDMs and
airway macrophages, expression of SAF lncRNA is reportedly
decreased in HIV-1–infected T cells that are susceptible to
virus-induced cell death (38). This raises the possibility that the
antiapoptotic lncRNA SAF is differentially regulated in macro-
phages and T lymphocytes during HIV-1 infection. This obser-
vation is consistent with the respective fate of these two cell types
following HIV-1 infection as delayed activation of caspase-3 and
apoptosis has also been associated with the impaired killing of
HIV-1–infected macrophages relative to CD4+ T cells by cytotoxic
T cells (49). A similar observation was also reported in macaques
where virus-specific CD8+ T cells failed to kill SIV-infected
Fig. 5. Effect of siSAF treatment on HIV-1 infection in MDMs. (A) Representative flow cytometry plots showing p24-positive HIV-1–infected cells in virus-
nonexposed and virus-infected MDMs with or without siRNA treatment, as indicated above the panel. Cells were gated for singlets (FSC-H vs. FSC-A) and
MDM (SSC-A vs. FSC-A) before analysis of HIV-1 p24 expression. (B) The percentage of viral p24-positive (mean ± SEM) HIV-1–infected cells was determined by
flow cytometry staining with PE-conjugated anti-p24 antibody in untreated, negative-control siRNA NC1-treated and siSAF-treated MDMs on day 1 (blue bar)
and day 3 (red bar) post siRNA-transfection (n = 4). (C and D) Fold changes (mean ± SEM) in expression of the viral Gag (C) and Nef (D) RNA was determined by
qRT-PCR in untreated, negative-control siRNA NC1-treated and siSAF-treated MDMs on day 1 (blue bar) and day 3 (red bar) post siRNA-transfection (n = 3).
Expression levels of housekeeping genes GAPDH, U6, and 18S rRNA was used to normalize data. (E) The amount of viral p24 protein (mean ± SEM) was
determined by ELISA in the supernatant of HIV-1–infected cells in untreated, negative-control siRNA NC1-treated and siSAF-treated MDMs on day 1 (blue bar)
and day 3 (red bar) post siRNA-transfection (n = 3). HIV, virus-infected and untreated; HIV-NC1, virus-infected and negative-control siRNA NC1-treated; HIV-
siSAF, virus-infected and siSAF-treated. Significance of difference among groups determined by one-way ANOVA is indicated above the groups, *P < 0.05,
**P < 0.01 and ***P < 0.001, ****P < 0.0001.
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macrophages and limit viral replication in these myeloid cells (50,
51). Moreover, bystander MDMs did not show a statistically sig-
nificant increase in SAF expression in comparison with virus-
nonexposed control MDMs. The data suggest that active viral
infection and/or replication, rather than mere exposure to the
HIV-1 virion, is required for induction of SAF lncRNA-dependent
cell survival in macrophages. Although a number of HIV-1 viral
proteins have been implicated in either inducing or inhibiting cel-
lular apoptotic pathways, further investigation would be needed to
ascertain any precise roles of viral proteins in modulation of this
prosurvival lncRNA.
Our data demonstrate that HIV-1–mediated evasion of in-
duction of apoptotic effector caspases in macrophages can be
effectively negated or subverted by siRNA-mediated down-
regulation of SAF expression. Most importantly, such genetic
modulation was highly specific because siRNA treatment in-
duced activation of caspase-3/7 and loss of cell viability in the
HIV-1–infected macrophages alone, leaving the bystander and
nonexposed cells unaffected. Our results also showed that this
selective targeting of the infected cells can result in a significant
decline in viral reproduction and burden. Indeed, transfection of
MDMs with siSAF reduced HIV-1 replication and virus production
by nearly twofold within 1 d of treatment. On day 1 posttransfection,
an increase in caspase-3/7 activity was associated with a corre-
sponding inhibition in virus replication even without a discern-
able decrease in cell viability. Although active caspase-3/7 is an
important effector in the induction of apoptotic pathway, recent
publications suggest that effector-triggered immunity or mito-
chondrial outer membrane permeabilization mediated activation
of caspase-3/7 might also induce other parallel pathways such as
inflammasome and IL-1β maturation (52, 53). The downstream
pathway(s) of siSAF-mediated activation of caspase-3/7 and
subsequent cell death remain somewhat enigmatic. However,
with a siRNA-based treatment approach, which would be tran-
sient, a single round of transfection was sufficient to sustain re-
duced levels of virus infection for at least 3 d. Such an anti-viral
effect could potentially be enhanced through multiple rounds of
treatment. The in vivo significance of these results is supported
by the demonstration that comparable up-regulation of the
lncRNA SAF is observed in HIV-1–infected macrophages from
the airways of HIV-1–positive individuals. Previous analysis of
BAL-derived macrophages in Malawi indicated that HIV-1 was
present predominantly in a subset of small alveolar macrophages
and that alveolar macrophages account for ∼80% of the myeloid
cells recoverable by BAL (14, 47). Interestingly, alveolar mac-
rophages are now known to originate from fetal stem cells early
in embryonic development and are capable of extended life span
measurable in years. Such long-lived tissue resident macrophages
would be perfect candidates as reservoirs for HIV-1 persistence,
especially if stabilized by cell survival programs such as driven by
the lncRNA SAF. Overall, this study emphasizes the role of
lncRNAs as an important regulator in the cellular response to
HIV-1 infection and pathogenesis as well as highlights the potential
of targeting long noncoding RNAs such as SAF as a future thera-
peutic intervention specifically aimed toward HIV-1–infected long-
lived reservoirs.
Materials and Methods
Virus Production and Infection. The HIV-1 infectious molecular clone, pWT/BaL
(HXB3/BaL, Catalog 11414), was obtained from the NIH AIDS Reagent Pro-
gram. The plasmid encoding HIV-1 molecular clone NL43-IRES-mCherry with
R5-tropic env (BaL) was generated by replacing the EGFP sequence with that
of mCherry in the original plasmid pBR43IeG-nef+ R5env (a kind gift from
Thorsten R. Mempel, Massachusetts General Hospital, Boston). Replication-
competent VSV-G pseudotyped HIV-1 virus was prepared by cotransfecting
293FT cells with the respective HIV-1 molecular clone and VSV-G expression
plasmid using Lipofectamine 3000 reagent (Life Technologies). Transfection
media was replaced with fresh antibiotic free DMEMmedia 8 h posttransfection.
After 72 h, cell culture supernatant containing HIV-1 virus was harvested,
centrifuged to remove cell debris, passed through 0.45-μm filter, and stored
at −80 °C in aliquots. Titer of the virus stock was determined by p24 ELISA
(RETROtek HIV-1 p24 antigen ELISA kit; ZeptoMetrix), and 50 ng/mL of virus
was used to infect MDMs.
MDM Differentiation and siRNA Transfection. Human monocytes were
obtained from peripheral blood mononuclear cells of healthy individuals by
counter current centrifugal elutriation with an average purity of >97%
(Elutriation Core Facility, University of Nebraska Medical Center). Monocytes
were maintained in DMEM media supplemented with 10% human serum,
100 U/mL penicillin, and 100 μg/mL streptomycin (Invitrogen). Cells were cultured
at 37 °C with 6% CO2 for 7–8 d to fully differentiate into macrophages (MDMs).
For siRNA treatment, 1.5 × 106 MDMs were transfected with either 10 nM
each of three Dicer-substrate short interfering RNAs (DsiRNAs) targeted to
SAF (hs.Ri.FAS-AS1.13; IDT) or a nonspecific control, NC1 (negative control
DsiRNA; IDT) using Viromer Blue transfection reagent (Lipocalyx) according
to the manufacturer’s instructions. Transfection efficiency was monitored
with a Cy3-labeled DsiRNA (IDT) control.
lncRNA Profiling and qRT-PCR. For comparative lncRNA expression analysis of
infected and bystander cells, fully differentiated MDMs were infected with
the replication-competent VSV-G pseudotyped NL43–IRES-mCherry-Bal virus.
On day 7 postinfection, cells were harvested by gentle scraping following a
10-min incubation in cold PBS, washed once, and processed with a Bio-Rad
S3 cell sorter to separate mCherry-positive HIV-1–infected and mCherry-
negative bystander cells. Similar to the HIV-1–infected culture, virus-
nonexposed MDMs were also passed through the cell sorter and recovered
as mCherry negative as an experimental control. Total RNA was extracted
from sorted cells using TRIzol reagent (Invitrogen) according to manufac-
turer’s instructions, followed by DNase treatment (Turbo DNA-free kit;
Invitrogen) to remove genomic DNA. The same amount of RNA was used for
cDNA synthesis and subsequent quantification of lncRNA expression using
the Human LncRNA Profiler qPCR Array kit (System Bioscience) and ABI 7500
Fast Real-time PCR system (Applied Bioscience) in accordance to the manu-
facturer’s protocol. Expression of SAF lncRNA was further independently
verified with previously published (43) primer sets (Forward primer: CAT CTC
AGC CTC TTG GTG TAA and Reverse primer: ATG GGA GAT ATG GGA TTG
AAC) and iTaq Universal SYBR Green Supermix (Bio-Rad). HIV-1 viral tran-
scripts were quantified by qRT-PCR of Gag (Forward primer: AAG CAC TGG
GAC CAG GAG C and Reverse primer: TGG TAG CTG GAT TTG TTA CTT GGC)
and Nef (Forward primer: TAG TGT GAT TGG ATG GCC TGC and Reverse
primer: ACA AGC ATT GTT AGC TGC TG), following a similar procedure.
Expression of the housekeeping genes: GAPDH (Forward primer: GAC AAG
CTT CCC GTT CTC AG and Reverse primer: GAG TCA ACG GAT TTG GTC GT),
U6 (Forward primer: CTC GCT TTG GCA CA and Reverse primer: AAC GCT
TCA CGA ATT TGC GT), and 18S rRNA (Forward primer: GGC CCT GTA ATT
GGA ATG AGT C and Reverse primer: CCA AGA TCC AAC TAC GAG CTT) was
used for normalization of qRT-PCR expression data.
Flow-Cytometry for HIV-1 p24 and Detection of Active Caspase-3/7.MDMs were
harvested by gentle scraping following a 10-min incubation in cold PBS. Cells
were stained for intracellular active caspase-3/7 enzyme using the CellEvent
Caspase-3/7 Green Detection reagent (Invitrogen) according to the manu-
facturer’s instruction with some modifications. Briefly, cells were resus-
pended in 1 mL PBS to which 1 μl CellEvent caspase-3/7 reagent was added
and then incubated at 37 °C for 30 min. During the last 10 min of incubation,
1 μL of Fixable Viability Dye eFluor 506 (eBioscience) was added to the cells.
Thereafter, the cells were washed with PBS and fixed and permeabilized
using 1× Cytofix/cytoperm solution (BD Bioscience) for 30 min. For detection
of HIV-1–infected MDMs, the cells were then stained with an antibody
against the HIV-1 core protein p24 (KC57-RD1; Beckman Coulter) for 30 min
at room temperature. Finally, the cells were fixed in 1% paraformaldehyde
in PBS and analyzed with a BD LSRII flow cytometer. Flow cytometry data
were analyzed using FlowJo software. Cells were first gated for singlets
[forward scatter height (FSC-H) vs. forward scatter area (FSC-A)] and macro-
phage [side scatter area (SSC-A) vs. FSC-A]. The macrophage gate was further
analyzed for expression of HIV-1 p24 protein and gated into bystander [p24-
phycoerythrin (PE) negative] and infected (p24-PE positive) MDMs. From these
gated populations, cell viability and apoptosis of bystander and infectedMDMs
were subsequently determined based on staining for viability dye eFluor
506 and active caspase-3/7, respectively.
Study Subjects and Bronchoalveolar Lavage. Bronchoalveolar lavage (BAL) was
obtained from four HIV-positive, antiretroviral treatment naive individuals
(aged ≥18 y) at the Queen Elizabeth Central Hospital in Blantyre, Malawi.





















Age, gender, plasma viral load, and CD4 T cell counts of the study partici-
pants at the time of bronchoscopy are listed in SI Appendix, Table S1. The
study received ethical approval from the research ethics committees of the
College of Medicine, Malawi (Research protocol P.10/08/708), the Liverpool
School of Tropical Medicine, UK (Research protocol 08.54), and Cornell Uni-
versity (Research protocol 908000698). All study participants provided written
informed consent.
FISH Staining and Flow Cytometry Sorting of BAL-Derived Airway Macrophages.
Cells isolated from whole BAL fluid were stained with predetermined optimal
concentrations of fluorochrome-conjugated monoclonal antibodies against
human cell surface proteins as detailed (47). Briefly, BAL cells (1 × 106 cells)
were incubated with anti-CD206 Brilliant Violet 421 and anti-CD169 Alexa
Fluor 647 antibodies for 15 min in the dark at room temperature. The cells
were washed, resuspended in PBS, and acquired on a BD LSRFortessa flow
cytometer (Becton Dickinson). Data were analyzed using FlowJo v10.5.0
(FlowJo LLC). FISH staining for HIV-1 Nef RNA in BAL-derived airway macro-
phages were carried out as previously described (14, 54). FISH-stained BAL
cells were first gated for singlets (FSC-H vs. FSC-A) and macrophages (SSC-A vs.
FSC-A) and then sorted into Nef-positive and Nef-negative cells based on
staining for HIV Nef-Quasar670 probes (LGC Biosearch Technologies) using a
BD FACS Aria cell sorter.
Statistical Analysis. Statistical analysis was performed using GraphPad Prism
software. Unless otherwise indicated, one-way ANOVA with Tukey’s multiple
comparison test was used for all statistical analysis and a P value below
0.5 was considered significant.
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